← brief for 2026-08-17 · People & money

Cost-effectiveness analysis comparison of etelcalcetide, paricalcitol, and cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.

Article No results yet Peer reviewed

Key takeaways

This study compared the cost and value of three drugs for overactive parathyroid glands, a common problem in kidney disease. It used a computer model of the Chinese health system over one year, not a new trial in patients. It reports which drug may give the best value for the money. There are no new results about how patients actually did.

Who did this work

Liang M · Liu S · Zhang X · Bai L · Fu Y

Source

Article · PubMed, Nutritional supplements and CKD · 2026 Aug 17
https://pubmed.ncbi.nlm.nih.gov/42606099/